Alkermes Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for ALKERMES, and what generic alternatives to ALKERMES drugs are available?
ALKERMES has six approved drugs.
There are twenty-eight US patents protecting ALKERMES drugs.
There are two hundred and twenty-four patent family members on ALKERMES drugs in thirty-four countries and thirteen supplementary protection certificates in eight countries.
Summary for Alkermes
International Patents: | 224 |
US Patents: | 28 |
Tradenames: | 6 |
Ingredients: | 5 |
NDAs: | 6 |
Patent Litigation for Alkermes: | See patent lawsuits for Alkermes |
PTAB Cases with Alkermes as petitioner: | See PTAB cases with Alkermes as petitioner |
PTAB Cases with Alkermes as patent owner: | See PTAB cases with Alkermes as patent owner |
Drugs and US Patents for Alkermes
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alkermes Inc | ARISTADA INITIO KIT | aripiprazole lauroxil | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 209830-001 | Jun 29, 2018 | RX | Yes | No | 8,431,576 | See Plans and Pricing | Y | See Plans and Pricing | |||
Alkermes Inc | LYBALVI | olanzapine; samidorphan l-malate | TABLET;ORAL | 213378-002 | May 28, 2021 | RX | Yes | No | 9,119,848 | See Plans and Pricing | Y | See Plans and Pricing | |||
Alkermes Inc | LYBALVI | olanzapine; samidorphan l-malate | TABLET;ORAL | 213378-004 | May 28, 2021 | RX | Yes | No | 11,241,425 | See Plans and Pricing | See Plans and Pricing | ||||
Alkermes Inc | LYBALVI | olanzapine; samidorphan l-malate | TABLET;ORAL | 213378-003 | May 28, 2021 | RX | Yes | No | 11,185,541 | See Plans and Pricing | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Alkermes
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Alkermes | VIVITROL | naltrexone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 021897-001 | Apr 13, 2006 | 6,379,704 | See Plans and Pricing |
Alkermes Inc | LYBALVI | olanzapine; samidorphan l-malate | TABLET;ORAL | 213378-002 | May 28, 2021 | 7,956,187 | See Plans and Pricing |
Alkermes | VIVITROL | naltrexone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 021897-001 | Apr 13, 2006 | 5,792,477 | See Plans and Pricing |
Alkermes | VIVITROL | naltrexone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 021897-001 | Apr 13, 2006 | 7,799,345 | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Alkermes Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Canada | 2766033 | See Plans and Pricing |
Japan | 2017048247 | See Plans and Pricing |
Denmark | 2608670 | See Plans and Pricing |
Australia | 2012231160 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Alkermes Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2316456 | 17C1058 | France | See Plans and Pricing | PRODUCT NAME: NALTREXONE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER CHLORHYDRATE DE NALTREXONE ET,BUPROPION OU SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER CHLORHYDRATE DE BUPROPION; REGISTRATION NO/DATE: EU/1/14/988 20150330 |
1675573 | 2014C/029 | Belgium | See Plans and Pricing | PRODUCT NAME: ARIPIPRAZOLE; AUTHORISATION NUMBER AND DATE: EU/1/13/882 20131119 |
2316456 | 1790064-8 | Sweden | See Plans and Pricing | PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE; REG. NO/DATE: EU/1/14/988 20150330 |
2316456 | 2017/059 | Ireland | See Plans and Pricing | PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/14/988 20150326 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.